AGE Company Profile and Key Details

Q: Who are the executives of AGE?

Ms. Judith SegallSec.Dr. Nafees Naseer Malik M.D.Chief Operating OfficerMs. Eun-Jae Park CPAChief Financial OfficerDr. Ivan LabatChief Information Officer

AMEX : AGE

AgeX Therapeutics

$11.10

-1.5-11.90%

At Close 4:00 PM

Not Actively Trading

71.04

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

AgeX Therapeutics, Inc. (AGE) stock declined over -11.90%, trading at $11.10 on AMEX, down from the previous close of $12.60. The stock opened at $12.59, fluctuating between $11.10 and $12.59 in the recent session.

Stock Snapshot

12.6

Prev. Close

27.76M

Market Cap

11.1

Day Low

-0.02300375106211013

P/E Ratio

-482.53

EPS (TTM)

-7.23

Cash Flow per Share

12.59

Open

2.5M

Number of Shares

12.59

Day High

97.82%

Free Float in %

5.07

Book Value

3.68K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 26, 2024	12.59	12.30	11.10	11.10	3.68K
Mar 25, 2024	12.53	13.37	12.17	12.60	4.36K
Mar 22, 2024	13.54	13.90	13.03	13.03	2.98K
Mar 21, 2024	13.00	14.00	13.00	13.29	8.5K
Mar 20, 2024	15.90	15.90	12.59	13.01	21.15K
Mar 19, 2024	15.40	16.01	13.52	14.53	16.04K
Mar 18, 2024	21.99	21.99	15.15	16.90	23.47K
Mar 15, 2024	15.00	22.32	11.51	22.32	24.85K
Mar 14, 2024	15.83	21.10	15.12	17.94	16.09K
Mar 13, 2024	16.18	22.83	14.77	14.77	40.03K
Mar 12, 2024	11.96	16.09	11.96	15.98	10.31K
Mar 11, 2024	12.59	13.30	11.96	12.24	2.92K
Mar 08, 2024	13.54	13.72	12.92	13.36	1.09K
Mar 07, 2024	13.36	13.72	12.66	13.36	1.72K
Mar 06, 2024	13.64	13.72	13.01	13.72	317
Mar 05, 2024	13.72	13.98	13.15	13.79	468
Mar 04, 2024	12.66	13.98	12.49	13.80	2.2K
Mar 01, 2024	13.66	13.89	13.01	13.01	594
Feb 29, 2024	13.05	14.03	12.70	13.40	1.49K
Feb 28, 2024	13.70	13.70	12.66	13.05	990

Contact Details

Alameda, CA 94501

United States

https://www.agexinc.com 510 671 8370

About Company

AgeX Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to pioneering and commercializing groundbreaking therapies that address human aging and degenerative conditions. The company's developmental pipeline features several promising cell-based therapeutic candidates: AGEX-BAT1: A cell therapy designed to manage various age-related metabolic disorders, including adult-onset Type II diabetes and obesity. AGEX-VASC1: A cell-based approach aimed at re-establishing vital vascular support in aged ischemic tissues, which could be relevant for conditions such as peripheral vascular disease and ischemic heart disease. Beyond cell therapies, AgeX is also exploring other modalities: Its primary drug candidate in the discovery phase is AGEX-iTR1547, a drug formulation focused on achieving scarless wound repair. For induced tissue regeneration, its leading biologic candidate is AGEX-iTR1550, which leverages gene delivery technology. Furthermore, AgeX maintains a research collaboration with the University of California at Irvine, jointly working to develop cellular therapies for various neurological disorders. Founded in 2017, AgeX Therapeutics, Inc. maintains its headquarters in Alameda, California.

Stock Peers

PTHS

0.21+0.85%

Pelthos Therapeutics Inc.$25.03 CYBN

0.1+1.22%

Cybin Inc.$8.28 NRXS

0.14+2.41%

NeurAxis, Inc.$5.95 ARMP

0.25+4.73%

Armata Pharmaceuticals, Inc.$5.53 APUS

-0.91-25.71%

Apimeds Pharmaceuticals US, Inc$2.63 SER

0.12+4.80%

Serina Therapeutics, Inc.$2.62 PLX

0.005+0.19%

Protalix BioTherapeutics, Inc.$2.59 CANF

-0.93-28.27%

Can-Fite BioPharma Ltd.$2.36 OSTX

0.05+3.01%

OS Therapies Incorporated$1.71 CVM

0.04+2.48%

CEL-SCI Corporation$1.65

Company Overview

AgeX Therapeutics, Inc. (AMEX:AGE) closed at $11.10 USD, losing -$1.50 (-11.90%) from the previous close of $12.60. The stock is currently within 5% of its 52-week low $10.90 and $35.17. With a market capitalization of about $27.76 million, AgeX Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.19). Key stats such as the average daily volume over the past year has been around 3.98 thousand shares, in line with its 52-week average. Headquartered in Alameda, CA, AgeX Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Eun-Jae Park CPA, the company employs approximately 4 people and listed since November 29, 2018. AgeX Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to pioneering and commercializing groundbreaking therapies that address human aging and degenerative conditions.

Technical Performance

AGE has shown weak momentum, losing -23.61% over the past week and -17.81% over the past quarter, though year-to-date performance is down -18.02%. Short-term trend indicators are mixed aligned (SMA20 -22.16%, SMA50 -20.62%, SMA200 -44.79%). The stock’s 14-day RSI is 41.06 (neutral), while the ATR of 2.58 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -68.44% below its high and over 1.81% above its low.

Valuation Metrics

AgeX Therapeutics, Inc. trades at a P/E ratio of -5.87, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 9.71 trading at moderately above to book value. The P/FCF stands at -1.31, also above market averages.

Dividend & Fair Value

AgeX Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.97. This means the shares are trading below this model’s fair value.

Shareholding & Insider Activity

AgeX Therapeutics, Inc. has 2.50 million shares outstanding. The public float is 2.45 million shares, elevated short interest at 0.01% of float. This equals 4.47 thousand shares. The short ratio is 3.88 days. Institutional investors hold 2250.0% of the float. Insiders own 4347.0%. Juvenescence Ltd holds 308.56 thousand shares, WEST MICHAEL D has 15.46 thousand shares and ESCARRA VICKI B has 5.49 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, AgeX Therapeutics generated $142.00K in revenue, or $0.13 per share. Gross margin was -20.42%, operating margin -7014.08%, and net profit margin -10424.65%. Returns are negative, with ROA at -123.72% and ROE at -270.67%.
On valuation metrics, AgeX Therapeutics trades at a P/E of -5.87, P/S of 0.00 and P/B of 9.71. The current ratio is 6.65 and quick ratio is 6.65. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -173.24.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, AgeX Therapeutics posted revenue of $142.00K, down slightly from $34.00K in the prior quarter. Gross profit was - $29.00K (margin -20.42%). Operating income was - $9.96M (margin -7014.1%). Net income was- $14.80M (EPS - $13.72).
The company ended the quarter with $345.00K in cash and short-term investments, a total debt of $4.37M, and net debt of $4.02M. Total assets were $11.97M, with equity of $5.36M. Financials further reflected weakness, with operating cash flow of - $7.80M, free cash flow of - $7.80M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that AgeX Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 33.69%, with price expected at $14.84 by April 09, 2024, within a range of $12.52 to $17.08 3-Month Outlook: Projected rise of 159.19%, reaching $28.77 by June 24, 2024, with a range of $28.64 to $28.89. 1-Year Outlook: Projected gain of 538.47%, with price at $70.87 by March 26, 2025, within a range of $70.72 to $71.02.

Key Takeaways

AgeX Therapeutics, Inc. (AMEX:AGE) shares are down -18.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows AgeX Therapeutics, Inc. trading at a premium to the broader market with a P/E of -5.87. Our AI forecast model points to short-term strength (33.69% over two weeks), a medium-term rise (159.19% over three months), and a longer-term gain (538.47% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current AgeX Therapeutics, Inc. (AGE) stock price?

AgeX Therapeutics, Inc. (AMEX: AGE) stock price is $11.10 in the last trading session. During the trading session, AGE stock reached the peak price of $12.59 while $11.10 was the lowest point it dropped to. The percentage change in AGE stock occurred in the recent session was -11.9% while the dollar amount for the price change in AGE stock was - $1.50.

AGE's industry and sector of operation?

The AMEX listed AGE is part of Biotechnology industry that operates in the broader Healthcare sector. AgeX Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AGE?

Ms. Judith Segall
Sec.
Dr. Nafees Naseer Malik M.D.
Chief Operating Officer
Ms. Eun-Jae Park CPA
Chief Financial Officer
Dr. Ivan Labat
Chief Information Officer

How AGE did perform over past 52-week?

AGE's closing price is 1.81% higher than its 52-week low of $10.90 where as its distance from 52-week high of $35.17 is -68.44%.

How many employees does AGE have?

Number of AGE employees currently stands at 4.

Link for AGE official website?

Official Website of AGE is: https://www.agexinc.com

How do I contact AGE?

AGE could be contacted at phone 510 671 8370 and can also be accessed through its website. AGE operates from 1101 Marina Village Parkway, Alameda, CA 94501, United States.

How many shares of AGE are traded daily?

AGE stock volume for the day was 3.68K shares. The average number of AGE shares traded daily for last 3 months was 3.98K.

What is the market cap of AGE currently?

The market value of AGE currently stands at $27.76M with its latest stock price at $11.10 and 2.5M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	4
Beta	1.19
Sales or Revenue	$142.00K
5Y Sales Change%	-0.734%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

AGE Company Profile and Key Details

AgeX Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Key Takeaways

Price Forecast & Outlook

Company Overview

Valuation Metrics